At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Blood sample (mrEMVI positive patient) (other), Blood sample (mrEMVI negative patient) (other)
- How long the study runs
- Study runs about 169 months (dates as stated)
- About the drug or intervention
- Blood sample (mrEMVI positive patient) — other: Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy.
- Patient visit burden
- Not specified by the sponsor
In plain English
This study looks at small pieces of DNA (genetic material) from cancer cells that can be found in the blood, called circulating tumour DNA (ctDNA). Researchers want to find out whether these DNA pieces are linked to signs on scans of cancer growing into large veins near the bowel, known as extramural venous invasion (EMVI). The study is for people with bowel (colorectal) cancer and is run by Imperial College London.
Who can take part
- You have bowel cancer confirmed by a tissue sample (biopsy), of a type called adenocarcinoma
- You are able to have surgery that aims to cure the cancer
- A CT (computed tomography) scan shows the cancer has not spread to other parts of the body
- You had your pre-surgery staging scan within six weeks before your surgery
- You have given written informed consent to take part
- You are aged 16 or over
Who may not be able to
- The cancer has spread to other parts of the body, including spread to the liver that could be removed with surgery
- You have been diagnosed with another cancer at the same time
- You cannot have the type of scan used to check for EMVI, because there is a medical reason the scan is not suitable for you
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 16 Years and over
- Who
- All
- Number of participants
- 100
- Started
- 2015-11
- Last checked
- 2024-10
Plain English Summary
What is this study?
- • Testing a new treatment for cancer
- • Clinical study - 100 participants
- • This study does not involve randomization or treatment
Who can take part?
- • Ages 16 Years and over
- • Diagnosed with cancer
Where?
- • Margate - Queen Elizabeth the Queen Mother Hospital
- • Hammersmith - St Mary's Hospital (Imperial)
- • Sutton - Royal Marsden Hospital NHS Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This study does not involve randomization or treatment. Eligible patients have colorectal adenocarcinoma with no metastases eligible for curative surgery. A pre operative staging scan must have been completed within 6 weeks prior to surgery. Two x 20ml blood samples will be taken from each patient, one prior to and one during or within 24hrs after surgery. Patients are annually followed up to 3 years.
More detail
A multicentre observational study, ctDNA aims to provide the evidence base for metatstatic disease being caused by vascular methods of spread by determining if there is a link between EMVI status and ctDNA
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 16 Years and over
- Who can join: All genders
What the study is looking for
- ✓Have a biopsy-confirmed colorectal adenocarcinoma
- ✓Is eligible for curative surgery
- ✓Has no that has spread disease on CT scan
- ✓Has completed pre-operative staging scan within six weeks prior to surgery
- ✓Have provided written agreement to take part to participate in the study
Who cannot take part
- ✗Have that has spread disease (including resectable liver metastases)
- ✗Have a synchronous second cancer
- ✗Are not safe to use for any imaging able to determine EMVI status
See the full criteria
Where Is This Study? (3 UK sites)
Queen Elizabeth the Queen Mother Hospital
Margate CT9 4AN, United Kingdom
St Mary's Hospital (Imperial)
Hammersmith W2 1NY, United Kingdom
Royal Marsden Hospital NHS Foundation Trust
Sutton SM2 5PT, United Kingdom
How to Get in Touch
Caroline Martin
Sponsor contactCONTACT
Syvella Ellis
Sponsor contactCONTACT